Tuberculosis updates 2018: Innovations and developments to end TB

Tuberculosis updates 2018: Innovations and developments to end TB The 2013 tuberculosis (TB) review series ‘Tuberculosis: Current state of knowledge’ highlighted important gaps in our existing knowledge on the complex interactions between the pathogen and the host. We also detailed major limitations in current control strategies. Since then, there have been major developments in new diagnostic tools and drugs/regimens for TB and latent TB infection (LTBI), some of which have modified clinical practice in both high‐ and low‐burden countries. In 2014, the World Health Assembly approved the ‘End TB Strategy’, which set ambitious targets to achieve a 95% reduction in TB death and 90% reduction in TB incidence rate by 2035. To consolidate developments and to meet the upcoming challenges, we have invited a panel of international experts to critically re‐examine the relevant issues in a new series of themed reviews focused on TB.Despite over two decades of effort to find and treat infectious sources, there were still an estimated 10.4 million incident TB cases with 1.7 million deaths in 2016. The annual decline of TB incidence remained at around 2%, not much higher than the annual decline of TB mortality of 1.71% in the United Kingdom in the pre‐chemotherapeutic era. Resistance has also emerged to most of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Respirology Wiley

Tuberculosis updates 2018: Innovations and developments to end TB

Loading next page...
 
/lp/wiley/tuberculosis-updates-2018-innovations-and-developments-to-end-tb-JF0ocrQsDx
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Asian Pacific Society of Respirology
ISSN
1323-7799
eISSN
1440-1843
D.O.I.
10.1111/resp.13244
Publisher site
See Article on Publisher Site

Abstract

The 2013 tuberculosis (TB) review series ‘Tuberculosis: Current state of knowledge’ highlighted important gaps in our existing knowledge on the complex interactions between the pathogen and the host. We also detailed major limitations in current control strategies. Since then, there have been major developments in new diagnostic tools and drugs/regimens for TB and latent TB infection (LTBI), some of which have modified clinical practice in both high‐ and low‐burden countries. In 2014, the World Health Assembly approved the ‘End TB Strategy’, which set ambitious targets to achieve a 95% reduction in TB death and 90% reduction in TB incidence rate by 2035. To consolidate developments and to meet the upcoming challenges, we have invited a panel of international experts to critically re‐examine the relevant issues in a new series of themed reviews focused on TB.Despite over two decades of effort to find and treat infectious sources, there were still an estimated 10.4 million incident TB cases with 1.7 million deaths in 2016. The annual decline of TB incidence remained at around 2%, not much higher than the annual decline of TB mortality of 1.71% in the United Kingdom in the pre‐chemotherapeutic era. Resistance has also emerged to most of

Journal

RespirologyWiley

Published: Jan 1, 2018

Keywords: ; ; ;

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve Freelancer

DeepDyve Pro

Price
FREE
$49/month

$360/year
Save searches from
Google Scholar,
PubMed
Create lists to
organize your research
Export lists, citations
Read DeepDyve articles
Abstract access only
Unlimited access to over
18 million full-text articles
Print
20 pages/month
PDF Discount
20% off